Analytical Validity Of The PAM50-based Prosigna™ Breast Cancer Prognostic Gene Signature Assay Is Published

A study, which looks at the analytical validity of PAM50-based Prosigna™ Breast Cancer Prognostic Gene Signature Assay, has been published in the BMC Cancer journal. The study which has been released by NanoString Technologies, Inc., a provider of range of life science tools for research and molecular diagnostic technologies is now available online. 

The study presents evidence of the Prosigna Assay on the nCounter Dx Analysis System.  The findings presented form the basis of a technique for assessing the risk of recurrence (ROR) in specific breast cancer patients. Research was conducted at the British Columbia Cancer Agency and Washington University. Until now, the complexity of testing has limited research to centralized reference laboratories. Brad Gray, President and Chief Executive Offier for NanoString Technologies commented on the success of the findings, “results from this analytical validation study demonstrate that the Prosigna Assay on the nCounter Dx Analysis System is user-friendly and that local laboratory pathologists can generate precise and reproducible results with the Prosigna Assay”.

The Prosigna Assay helps in the assessment of potential recurrence of breast cancer in patients at the 10 year marker.  It has been noted that the Prosigna Assay is not designed for use to diagnose, detect or to select therapy approaches for a patient. NanoString Technologies’ are designed to offer efficient and cost sensitive ways to profile genes with a high level of accuracy. The company is responsible for developing wide ranging research and medicine tools to include biomarker discovery and validation. The nCounter-based Prosigna™ Breast Cancer Prognostic Gene Signature Assay is a first of its kind to be promoted via the company’s diagnostic business.